1	Characteristics and antiviral treatment eligibility of newly
2	diagnosed hepatitis B patients at a teaching hospital in
3	Ghana: Implications for prevention and management
4	
5	
6	Joseph Daniels <sup>1,2*</sup> , Yvonne A. Nartey <sup>3</sup> , Francis Djankpa <sup>4</sup> , Jacques Simpore <sup>5</sup> , Dorcas Obiri-
7	Yeboah <sup>2</sup>
8	
9	
10	<sup>1</sup> National Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching
11	Hospital, Accra, Ghana
12	<sup>2</sup> Department of Microbiology and Immunology, School of Medical Sciences, University of
13	Cape Coast, Cape Coast, Ghana
14	<sup>3</sup> Department of Internal Medicine and Therapeutics, School of Medical Sciences, University
15	of Cape Coast, Cape Coast, Ghana
16	<sup>4</sup> Department of Physiology, School of Medical Sciences, University of Cape Coast, Cape
17	Coast, Ghana
18	<sup>5</sup> Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso
19	
20	
21	* Corresponding author
22	Email: j.daniels@kbth.gov.gh (JD)
23	
24	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 25 Abstract

26 Hepatitis B virus (HBV) infection poses a considerable public health challenge in limited-27 resource settings especially in the sub-Saharan African region. Even though HBV infection is 28 incurable, timely treatment is effective in preventing disease progression to liver cirrhosis or 29 hepatocellular carcinoma. However, not all infected patients require treatment. The aim of this 30 study was to determine the clinical, immunological, and virological profiles of newly 31 diagnosed adult HBV patients at a tertiary healthcare center in Ghana and to determine the 32 antiviral treatment eligibility rate based on current guidelines of the World Health Organization 33 (WHO). A hospital-based cross-sectional study involving total sampling of 220 treatment naïve 34 HBV surface antigen positive clients was carried out. A structured questionnaire was used to 35 collect data and detailed clinical and laboratory assessment (serological, biochemical and 36 virological) was carried out. Data were entered and analyzed with STATA version 16. The median age at diagnosis was 34 years (IQR 26.0 - 41.5) with a male to female ratio of 1:1.5. 37 38 A total of 138 participants (62.7%) were diagnosed with HBV infection following voluntary 39 testing. There was a median delay of 8.5 months (IQR 3.0 - 22.5) between initial diagnosis and 40 patients' presentation for medical care. In all, 24 patients (10.9%) had abnormal clinical 41 examination findings, 172 patients (78.2%) had HBV DNA levels  $\leq$  2000 IU/ml while 8 (3.6%) 42 were seropositive for HBeAg. A small proportion of patients had concomitant human 43 immunodeficiency virus (2.7%) and hepatitis C virus (1.4%) infections. Treatment eligibility 44 rate was very low among newly diagnosed HBV infected patients seeking medical care (n=14, 45 6.4%) following the WHO guidelines for treatment eligibility. Thus, increasing screening rate 46 among the general population, early linkage to clinical care of screen positives and vaccination 47 of screen negatives will help reduce HBV related clinical conditions in resource limited 48 countries.

### 49 Keywords

50 HBV DNA, HBV/HCV coinfection, HBV/HIV coinfection, hepatitis B infection

51 hepatitis B, immunological profile, hepatitis B, treatment eligibility

52

### 53 Introduction

54 Estimated global prevalence rates in 2022, based on data from 170 countries suggest that 55 about 257.5 million individuals worldwide have confirmed hepatitis B virus (HBV) infection 56 [1]. About 0.5% of infected people yearly seroconvert spontaneously from being hepatitis B 57 surface antigen (HBsAg) positive to becoming hepatitis B surface antibody (HBsAb) positive 58 [2]. The overall global lifetime risk of HBsAg seropositivity is estimated to be more than 60%59 [3]. The World Health Organization (WHO) estimates the occurrence of 1.5 million new 60 infections around the globe every year. HBV infects the liver and is known to be a major global 61 cause of both acute and chronic hepatic diseases [4]. HBV infection is also reported to be the 62 cause for about 50 - 80% of all diagnosed cases of hepatocellular carcinomas (HCC) globally 63 [5]. Additionally, it is estimated to cause between 500,000 and 1.2 million deaths worldwide 64 annually through chronic hepatitis, and associated complications such as liver cirrhosis and HCC [6]. 65

HBV infection poses a considerable public health challenge in the developing world especially African countries [7]. In Africa unlike other regions of the world, HCC and liver cirrhosis develop at an earlier age among patients with HBV infection, and are generally associated with poorer prognosis [8]. The highest prevalence of HBsAg seropositivity is found in the WHO Western Pacific Region and Africa with 116 million and 81 million people respectively reported to be chronically infected [4]. In Ghana, there is high (>8%) prevalence of hepatitis B infection per the WHO classification [9]. Different experts have reported national

73 prevalence rates of 8.48% [10], 10-15% [11] as well as 12.92% [2]. However, a recent meta-74 analysis of 21 studies conducted in Ghana between 2015 and 2019 reported hepatitis B infection rates of 8.36% and 14.3% among adults and adolescents respectively [12]. HBV 75 76 infection requires great attention in Ghana due to its significant public health importance. 77 HBsAg detection remains the primary tool for the screening of individuals for HBV in sub-78 Saharan Africa [13]. A positive test for HBsAg for more than 6 months coupled with 79 seropositivity for hepatitis B core immunoglobulin G (HBcAb – IgG) imply disease chronicity 80 with increased risk of developing cirrhosis, hepatic decompensation and HCC [14].

81 Not all patients who test positive for HBsAg require treatment. Patients' eligibility for 82 the commencement of antiviral therapy is dependent on key factors such as age, HBV viral 83 load, serum Alanine Transaminase (ALT) levels, Aspartate to Platelet Ratio Index (APRI), 84 clinical evidence of liver cirrhosis, hepatitis B envelope antigen (HBeAg) status, concomitant 85 hepatitis C virus (HCV) or human immunodeficiency virus (HIV) coinfection and pregnancy status among females [15, 16]. It is important to accurately classify patients based on these 86 87 parameters, since this directly influences clinical decisions regarding antiviral therapy. These 88 parameters are also important in identifying patients at risk of progression to liver cirrhosis or 89 cancer, and as such determine which individuals require immediate initiation of antiviral 90 therapy.

With the high endemicity of chronic HBV (CHB) infection in Ghana, it is important to determine the proportion of HBV patients who require treatment. It is equally important to identify those who present for the first time with complications such as cirrhosis, hepatic decompensation and HCC, since this highlights missed opportunities for the care and management of persons living with HBV. The aim of this study was to determine the clinical, immunological, and virological profiles of newly diagnosed adult HBV infected patients at a

97 tertiary healthcare facility in Ghana and to determine the antiviral treatment eligibility rate98 based on WHO guidelines.

99

### 100 Methods

### 101 Study design and setting

102 This was a hospital-based cross-sectional study. Participants were recruited into the 103 study from the viral hepatitis/ sexually transmitted infections (STIs) clinic at the Cape Coast 104 Teaching Hospital (CCTH) which is situated at the northern part of the Cape Coast metropolis 105 in the Central Region of Ghana. CCTH is a 400-bed capacity hospital that serves as the tertiary 106 care referral center for both private and public healthcare institutions in the central and western 107 region of Ghana. The clinic started operating in 2009 and had registered about 3000 clients 108 with HBV infection by 2021. CCTH provides comprehensive HBV care and runs a specialist-109 led gastrointestinal (GI) and hepatology clinic that manages patients with diseases of the GI 110 and hepatobiliary tracts including those with complications related to viral hepatitis such as 111 liver cirrhosis and hepatocellular carcinoma.

### 112 Study Participants

113 Participants were recruited over a cumulative period of 11 months from December 10, 114 2019 to June 09, 2020 and November 03, 2020 to February 09, 2021 due to interruptions to the 115 operations of the clinic caused by the COVID-19 pandemic. Samples were collected at the 116 clinic once a week. There was total population sampling of all newly diagnosed clients with HBV infection who were seeking clinical care at CCTH during the sampling period. Patients 117 118 included in this study were treatment naïve adult clients who were 18 years or older, with a 119 positive HBsAg test who provided written informed consent. All patients with known 120 HBV/HIV coinfection who were already on highly active antiretroviral therapy (HAART) were

excluded from the study as well as individuals on antiviral therapy for other conditions if their
medications were known to be simultaneously active against HBV infection. All patients who
had been previously treated for HBV infection were also excluded from the study.

### 124 Study size

All clients attending the clinic who met the inclusion criteria (n=231 over the recruitment period) were offered the opportunity to be part of the study. However, 11 (4.8%) eligible clients declined to provide informed consent to participate in the study for personal reasons. In all, 220 patients were recruited into the study.

### 129 Ethical considerations

The study was approved by the institutional review board of CCTH (Reference number: CCTHERC/EC/2019/084). All patients' information including laboratory test results were kept private and confidential. The data of the participants were anonymized prior to analysis. Throughout this study, there was strict adherence to the prescribed standards of acceptable scientific and ethical behavior. All relevant COVID-19 protocols were observed during interactions with patients and data collection. All the study participants provided written informed consent prior to their recruitment into the study.

### 137 **Data sources**

Data regarding socio-demographic characteristics, past medical and family history as well as other relevant factors linked to HBV infection were collected through a structured questionnaire which comprised 32 closed-ended questions. Relevant data were also abstracted from patients' hospital records with their consent. The questionnaire was pretested in a similar out-patient setting to determine its validity and reliability to ascertain its appropriateness for this study. Twenty-two (22) clients were selected for pretesting, representing 10% of the actual sample size. Tau-equivalent reliability, also known as Cronbach's Alpha ( $\alpha$ ) was computed to

determine the reliability coefficient. The Alpha value obtained was 0.72 (number of items =
32), therefore this research instrument was deemed reliable and acceptable for collecting useful
data for the study.

### 148 Laboratory Procedures / Analysis

149 Single-use commercially available First Response® HBsAg rapid test kits (Premier 150 Medical Corporation Private Limited, India) were used to qualitatively detect HBsAg in the plasma specimen of patients [17]. Using the COBAS® AmpliPrep / COBAS® TaqMan® 151 152 HBV Test, version 2.0 (Roche, Switzerland) (CAP-CTM) and in accordance with the 153 manufacturer's instructions, the HBV viral load was measured from 400µl of patients' blood 154 [18]. The Biopanda HBV Combo Rapid Test (RAPG-HBV-001) (Biopanda, United Kingdom) 155 was utilized to qualitatively detect HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb in patients' 156 blood samples. The ChemWell® 2910 Automated EIA and Chemistry Analyzer (Awareness 157 Technologies, USA) was used to measure serum electrolytes, blood urea nitrogen (BUN) and 158 liver enzymes including aspartate and alanine transaminases, strictly following the 159 manufacturer's protocol. Complete blood counts (CBCs) were determined using the Mindray BC-2800 Auto Hematology Analyzer (China) [19]. All the patients were also tested 160 for HIV infection using the First Response<sup>®</sup> HIV 1-2.0 test (Premier Medical Corporation 161 Private Limited, India), OraQuick® HIV test (OraSure Technologies, USA) and SD 162 163 Bioline<sup>™</sup> HIV-1/2 antibody test kits (Abbott, USA) based on the guidelines for HIV screening 164 and diagnosis among adults, pregnant women and adolescents in healthcare settings [20]. 165 Single use commercially available HCV rapid test kits (Advanced Diagnostic Kit for 166 immunoglobulin to HCV, China) were used to qualitatively detect the presence of anti-HCV 167 immunoglobulins in patients' samples with sensitivity of 99.0% and specificity of 99.8% [21]. APRI calculation was based on hematological and biochemical tests conducted on patients' 168 169 samples. APRI was computed with the formula (AST/40/ platelet count  $(10^{9}/L) \times 100)$  [22].

### 170 Statistical analysis

171 Data were anonymized, coded, statistically cleaned, and analyzed using STATA statistical software package version 16 for Microsoft windows (Stata Corp). A combination of 172 173 descriptive and inferential statistics was performed. Socio-demographic and other 174 characteristics of participants were presented as frequencies with percentages. Histogram and Shapiro-Wilk's test were used to assess normality of the data. Means and standard deviations 175 176 were used for normally distributed data while median and interquartile range were used for 177 skewed data. For this study,  $p \le 0.05$  was considered statistically significant at a 95% confidence interval. 178

179

### 180 **Results**

### 181 Socio-demographic and behavioral characteristics

In total, 220 individuals with confirmed hepatitis B viral infection participated in this study. A total of 131 (59.6%) of the participants were female whereas 109 (40.4%) were male. There were more females than males in all age categories (Fig 1).

185

### 186 Fig 1. Percentage distribution of patients by age and gender.

187

The median age was 34 years (IQR 26.0 - 41.5). One hundred and eight (49.0%) were single whilst the remaining (n=112, 51.0%) were either married, divorced, or widowed. Majority (n=143, 65.0%) were sexually active. The median interval between initial diagnosis and presentation at the clinic was 8.5 months (IQR 3.0 - 22.5), with about a third of the patients (61.8%) attending their first visit to the clinic more than a year after initial diagnosis (Table 1).

#### Table 1. Socio-demographic and behavioral characteristics (n=220).

	Categories	Number (n)/	Percentage (%)/
Variables		Median	IQR
	Median	34	26.0 - 41.5
Age (vears)	≤ <b>3</b> 0	83	37.7
	31 - 50	110	50.0
	> 50	27	12.3
	Single	108	49.0
Marital status	Married	100	45.5
	Divorced/	12	5.5
	Widowed		
Sexual activity	Active	143	65.0
	Inactive	77	35.0
Pregnancy status of	Pregnant	9	6.9
females (n = 131)	Not-pregnant	122	93.1
	Median	8.5	3.0 - 22.5
Time since initial	≤ 1	136	61.8
diagnosis (years)	1-5	65	29.6
	> 5	19	8.6
History of alcohol	Yes	30	13.6
intake	No	190	86.4

Variables	Categories	Number (n)/	Percentage (%)/
		Median	IQR
Smoking habit	Smokers	6	2.7
	Non-smokers	214	97.3

### 198 IQR: interquartile range

199	Most of the participants ( $n = 138, 62.7\%$ ) were initially diagnosed with HBV infection
200	due to voluntary testing whereas 19 females (8.6%) were diagnosed as part of routine ANC
201	screening. A few ( $n = 8, 3.6\%$ ) were diagnosed through screening after the diagnosis of close
202	associates (sexual partners & family members) whereas the remainder (n=55, 25.0%) were
203	diagnosed after testing pursuant to the recommendation of a health-worker (Fig 2).

204

## Fig 2. Circumstances leading to initial diagnosis among study participants (n = 220).

ANC: antenatal care.

207

Approximately 60.9% did not know the HBsAg status of their immediate family members whereas 20.5% had a positive family history of HBV infection. In all, 15 (6.8%) had parents with HBV infection as illustrated in Fig 3.

211

# Fig 3. Distribution of HBV seropositive family members and sexual partners of the study participants.

214

In all, 24 patients (10.9%) had abnormal clinical examination findings. There were 12
patients (5.5%) who had icterus (jaundice), whereas 3 (1.4%) had hepatomegaly as illustrated

- 217 in Fig 4 which shows the distribution of clinical examination findings among patients. Two
- 218 patients (0.9%) each had abdominal distension and other stigmata of chronic liver disease
- 219 (CLD).
- 220
- 221 Fig 4. Distribution of clinical examination findings among patients.
- 222 CLD = chronic liver disease.
- 223 Laboratory characteristics of patients
- Most of the participants had aspartate transferase (AST) and alanine transaminase (ALT) levels within the normal range, 131(59.6%) and 195 (88.6%) respectively. One hundred and eighty participants (81.8%) also had alkaline phosphatase (ALP) levels within the normal range as shown in Table 2.
- 228

Variables	Categories	Number	Percentage
variables		(N =220)	(%)
AST (U/I)	Normal (0 – 31)	131	59.6
	Elevated (> 31)	89	40.4
	Low (< 13)	7	3.2
ALT (U/I)	Normal (13 – 69)	195	88.6
	Elevated (> 69)	18	8.2
	Low (<50)	15	6.8
ALP (U/I)	Normal (50 – 250)	180	81.8
	Elevated (> 250)	25	11.4
Direct bilirubin	Low (< 2)	28	12.7

229 **Table 2. Liver function tests of study participants.** 

					_
230	(µmol/l)	Normal (2 – 11)	163	74.5	
231		Elevated (> 11)	29	13.2	
232		Low (< 35)	33	15.0	
233	Albumin (g/dl)	Normal (35 -52)	178	80.9	
234		Elevated (> 52)	9	4.1	
235					I
236					
237					
238					
239					
240					
241					
242					
243					
244					
245					
246					
247 248 249 250	AST: Aspartate tran	nsferase, ALT: Alanine	transaminase	, ALP: Alkalino	e phosphatase
251	There was a s	mall proportion of patie	ents who had c	concomitant HI	V and HCV infections,
252	2.7% and 1.4% resp	pectively. Most of the p	atients (n = 8	5, 187%) had a	spartate - platelet ratio
253	index (APRI) score	es > 0.5. Also, 172 pati	ents (78.2%)	had HBV DN	A levels $\leq 2000 \text{ IU/ml}$
254	whereas 21.8% (n =	= 48) had levels > 2000	IU/ml. Only	one patient (0.5	5%) had an HBV DNA
255	titer > 20,000 IU/m	l (Table 3).			

### **Table 3. Other laboratory parameters of study participants.**

Clinical parameters	Variables	Number	Percentage
Common parameters		1 (umber	(%)
HIV Status	Positive	6	2.7
	Negative	214	97.3
HCV Status	Positive	3	1.4
	Negative	217	98.6
	< 0.5	33	15
APRI score	0.5 - 2.0	186	84.5
	> 2.0	1	0.5
HBV DNA	< 2000	172	78.2
(IU/ml)	2000 - 20,000	47	21.3
	> 20,000	1	0.5

258 HIV: human immunodeficiency virus, HCV: hepatitis C virus, APRI: aspartate-platelet ratio

259 index, HBV: hepatitis B virus, DNA: deoxyribonucleic acid

260

The proportion of patients who tested positive for HBsAb and HBcAb were 6 (2.7%) and 170 (77.3%) respectively. Also, 8 (3.6%) were seropositive for HBeAg whereas 177 (80.5%) showed seropositivity for HBeAb (Fig 5).

264

**Fig 5. HBV serological profile of patients.** HBsAb: hepatitis B surface antibody, HBeAg:

hepatitis B envelope antigen, hepatitis B envelope antibody, hepatitis B core antibody

### 268 **Treatment Eligibility**

269 In all, 14 participants (6.4%) were eligible for immediate initiation of antiviral therapy 270 based on WHO guidelines [23]. This group comprised 8 (57.1%) males and 6 (42.9%) females 271 (Table 4). All patients with e-antigen positive chronic hepatitis and/or APRI > 2 (HBV related 272 cirrhosis or advanced fibrosis) required treatment as well as individuals with HCV/HIV 273 coinfection and HCC. Among HBeAg-positive patients, treatment was required if ALT > 2xULN or viral load  $\geq$  20,000IU/ml. For HBeAg-negative patients, indications for treatment were 274 275  $ALT \ge 2x$  ULN or viral load  $\ge 2000IU/ml$ . None of the pregnant females in the study were 276 found to be eligible for immediate commencement of antiviral therapy for HBV infection. 277

### 278 Table 4. Characteristics of patients who were eligible for antiviral therapy.

Antiviral treatment eligibility	Number n/N	Percentage (%)
No antiviral treatment required	206/220	93.6
Treatment required:	14/220	6.4
Sex		
Male	8/14	57.1
Female	6/14	42.9
HBeAg status		
Positive	8/14	57.1
Negative	6/14	42.9
Serum ALT (U/l)		
$\leq 2x$ ULN	0/6	0
> 2x ULN	6/6	100

Number n/N	Percentage (%)
0/6	0
6/6	100
1/14	7.1
0	0
0	0
13	92.9
6/14	42.9
3/14	21.4
	Number n/N 0/6 6/6 1/14 0 0 13 6/14 3/14

HBeAg: hepatitis B envelope antigen, ALT: Alanine transaminase, ULN: upper limit of normal 279 range, APRI: aspartate-platelet ratio index, USG: ultrasonography, HCC: hepatocellular 280 281 carcinoma, HIV: human immunodeficiency virus, HBV: hepatitis B virus, HCV: hepatitis C 282 virus.

283

#### Discussion 284

285 This study aimed to describe the clinical, immunological, and virological characteristics 286 of newly diagnosed HBV clients and assess their eligibility for antiviral treatment based on the current WHO guidelines [23]. The median age of the participants in this study of 34 years is 287 288 comparable to the results of previous studies that were also focused on adult HBV patients  $\geq$ 289 18 years. In a meta-analysis of 30 peer reviewed publications with a population pool of over

290 100,000 Ghanaians, the authors reported the highest prevalence of HBV infection amongst 291 patients aged between 16 and 39 years [13].In sub-Saharan Africa, HCC has been reported to 292 develop at a mean age of 33 years [24].Individuals aged between 31 and 40 years have been 293 linked with a five-fold increase in the risk of HBV infection relative to other age groups 294 (P=0.009). The age range reported in this study represents both the reproductive and most 295 productive age groups in the Ghanaian society and may imply loss of productivity due to 296 absence from work for hospital visits and other economic activities among these patients.

297 There were 42 more females than males in our study population, representing 19.1% of 298 the total number of study participants. Two previous studies also reported a trend of higher 299 numbers of females compared to males in their studies involving patients with hepatitis B 300 infection [25, 26]. This study found a female to male ratio of 1.5:1 which can be partly 301 accounted for by the disparity in the general health seeking behavior among both sexes [27]. 302 Women are more at risk of contracting STIs than men [28]. This translates into a higher 303 likelihood of disease transmission from men to women than vice versa [28]. Another study 304 confirmed the existence of gender disparity in the prevalence of infections caused by HBV 305 [29]. HBV infection is classified as a viral sexually transmitted disease together with other 306 infections such as HIV, HCV, HPV and HSV. Majority of the patients (65.0%) were sexually 307 active whereas the remainder were inactive. Sexual contact is key in the transmission HBV 308 infection among adults in areas with very high prevalence rates including Ghana. In Ghana, 309 mother-to-child transmission, unprotected intercourse, and transfusion of contaminated blood 310 are the three main ways that HBV is spread [30].

In our study, we found that 63.3% of the patients did not have any knowledge about the status of their partners. This finding is not in keeping with the current WHO recommendation of routine screening of partners of all patients diagnosed with HBV [31]. Infection of an individual with HBV puts all close associates and immediate contacts such as spouses, sexual

partners, and household members at a high risk of getting infected. Disclosure of one's positive
HBsAg status to such exposed close contacts is vital in the prevention or alleviation of the risk
of transmission of HBV infection.

318 The disclosure of positive HBV status is very important for several reasons. First, it 319 provides an opportunity for the diagnosed individual to receive social support [32]. Close 320 contacts may be more likely to observe social protocols that will reduce their risk of being 321 infected (such as not sharing personal items like razor blades, nail cutters, tooth brushes or 322 anything that could have trace amounts of blood on them) and might be even more open to 323 HBV vaccination. Further studies are needed to explore the impact of HBV status disclosure 324 on the adoption of preventive measures and vaccination uptake among family members and 325 close associates of infected patients in the Ghanaian setting. Knowledge of the positive 326 diagnosis of a close contact is also an indication for HBsAg testing which will help in detecting 327 positive cases in family groups. Disclosure can also motivate other seropositive family 328 members to seek care thereby reducing their chance of developing cirrhosis and HCC.

In a study published in 2020 that investigated the disclosure of CHB status among HBV infected patients in Ghana, it was reported that patients were more likely to disclose their status under some conditions and for some reasons than others [33]. Reasons for disclosure included the desire to have close contacts tested and vaccinated, willingness to confide in the target of disclosure and the need for social and/or financial support. On the contrary, non-disclosures were on account of phobia for stigmatization and past undesirable experiences associated with disclosure.

Most of the participants were initially diagnosed via voluntary testing (62.7%) followed by health worker recommendation (25.0%). Similar findings were reported in a previous study that demonstrated that individuals with HBV infection were diagnosed because of self or physician-initiated testing, testing during screening programs and ANC testing [26, 34]. The

findings of this study indicate that voluntary testing for HBsAg among the adult population is very important in HBV infection case detection. Community based or opportunistic screening undoubtedly remains an effective tool in picking up positive cases in the general population.

In our study, we found that majority of the patients (60.9%) were not aware of the HBsAg status of their immediate family members. Out of those who knew the status of their family members (n=85), majority (n=45, 52.9%) had family members who were known to be seropositive for HBsAg. Therefore, the actual number of patients with a positive family history for HBV infection is likely to be far greater. These findings suggest that intrafamilial spread of HBV infection may be a potential mode of transmission in Ghana, and further studies are needed to fully elucidate this theory.

350 The overall prevalence rate of HBsAg positivity was 20.5% among household members 351 of patients which is comparable to the rate of 23.3% reported in Iran [35]. A 2024 study in 352 Mwanza, Tanzania however reported a much lower HBV prevalence rate of 5.4% among 353 household contacts of index cases [36]. After testing positive for sexually transmitted diseases 354 like HIV and HBV, some individuals are more prone to concealing their diagnosis than seeking 355 medical attention due to stigmatization [37]. CHB infection is an incurable disease and hence, 356 some people may not want to be associated or tagged with this diagnosis. A qualitative study 357 on chronic hepatitis B stigma in Ghana found that people with hepatitis B experience societal 358 stigma underlined by the belief that HBV is a highly contagious and severe disease as well as 359 the notion that HBV infection arises due to curses [38]. The question of "the most probable 360 source of transmission" arises when individuals test positive for STIs. Some HBV positive 361 patients may not wish to disclose their status to their close contacts which will prompt them to 362 get tested. If this testing turns out positive, they would likely be viewed as the source of the 363 infection in the household simply because they were diagnosed first, though it could be the 364 other way around. Nondisclosure of HBsAg positive status to close contacts increases their risk

of contracting the disease. It also robs them of an indication for testing and treatment as wellas possibly HBV vaccination if eligible.

367 The median time interval between patient's initial diagnosis and presentation at the 368 specialist clinic was 8.5 months (IQR 3.0-22.5). Majority (61.8%) were seen < 1 year whereas 369 8.6% were seen > 5 years after initial diagnosis. The reasons for this delay in presentation at 370 the specialist clinic may be associated with both patient and primary care provider factors. In 371 several African countries including Ghana, many patients who test positive for HBsAg during 372 opportunistic screening are unable to afford the additional tests or the cost of therapy because 373 it must be paid for out-of-pocket [10, 13, 39]. As a result, a lot of patients who test positive for 374 HBV do not proceed immediately to seek medical care or do not complete the required initial 375 evaluation to determine what needs to be done for them. In Ghana, anecdotal evidence suggests 376 that some patients resort to traditional and/or herbal remedies for the initial management of 377 STIs such as HIV, HCV, and HBV as well as other health conditions including cancer, diabetes, 378 hypertensive heart disease and bronchial asthma[40-42]. As a result of this exploration and 379 experimentation with unorthodox medicine it is possible that some patients may present late to 380 the hospital after all other avenues have failed or when there is disease progression.

381 According to the WHO, as of 2019, 10.5% of all the people estimated to be HBsAg positive already knew their positive status whereas only 22% of those diagnosed were receiving 382 383 medical care [4]. This points to the fact that a huge proportion of HBV infected patients do not 384 receive medical care after their diagnosis. Additionally, certain impediments to HBV treatment 385 and care have been reported including barriers relating to sociocultural beliefs and health 386 systems. These sociocultural beliefs include the perception that HBV is a spiritual disease and 387 a form of punishment from God. On the individual level, some patients take HBV infection for 388 granted owing to the absence of specific symptoms of CHB [33]. Furthermore, the financial 389 burden of hospital-centered treatment for HBV infection is considerably high and even

390 prohibitive for some patients [43]. In Ghana, unlike patients with HIV or HBV/HIV 391 coinfection, HBV mono-infected patients must pay for their medications out of pocket in 392 addition to the cost of their routine investigations such as LFT, HBV immunological profile 393 and hepatitis B viral load. The inclusion of medications, laboratory analysis and other 394 investigations under the National Health Insurance Scheme (NHIS) could potentially remove 395 this barrier at least partially if not completely. Similar to findings in other countries such as 396 Burkina Faso and Australia, the delay in seeking care for HBV infection could also be because 397 of stigmatization (or fear of it thereof), lack of knowledge and misconceptions about HBV 398 treatment as well as long queues and waiting times at treatment facilities [44, 45].

399 Hepatitis B infection is known to be self-limiting in 95% of adult cases and 5-15% of 400 cases among children under five years. According to WHO, 6.6 million (22%) of the people 401 diagnosed with HBV were on treatment as of 2019. The percentage of patients diagnosed with 402 HBV in Ghana who require treatment as well as the proportion of these treatment eligible 403 patients who receive the required treatment is unknown. In 2021 the proportion of CHB patients 404 worldwide who required treatment was about 12 - 25% (WHO 2021). There is no specific 405 treatment for acute hepatitis B unless the patient has acute hepatic failure, but for most patients, 406 antiviral treatment for CHB is lifelong. This has direct cost implications and potential financial 407 toxicity.

Treatment for viral hepatitis in Ghana is based on the National Guidelines for Prevention, Care and Treatment of viral hepatitis which is in line with the treatment recommendations of the World Health Organization. Approved antiviral agents for treatment of HBV infection in Ghana include Tenofovir disoproxil fumarate, Entecavir, pegylated interferon and Emtricitabine among several others. The treatment eligibility rate of 6.4% reported in this study is much lower than the reported rate of 46.8% in the United States [46]. This low rate implies that a significant proportion of the patients were diagnosed at a stage of

415 the disease that required close monitoring but did not warrant the immediate initiation of 416 expensive antiviral therapy which is not affordable for many patients.

417 Early and appropriate initiation of therapy for HBV infection is important in the 418 reduction of the risk of transmission and development of fatal long-term complications. To be 419 able to accomplish the WHO goal of eliminating viral hepatitis by the year 2030, it is important to not only precisely estimate treatment eligibility rates but also to ensure high treatment rates. 420 421 To the best of our knowledge based on currently available literature this is the first study that 422 evaluates treatment eligibility (rate) among HBV infected patients seeking medical care in the 423 Central Region of Ghana. Evaluation of treatment rate i.e., proportion of patients eligible for 424 treatment who receive antiviral treatment was beyond the scope of this study and remains an 425 outstanding question for future studies.

426

### 427 Limitations

This study was conducted among patients who had voluntarily reported at the HBV/other STIs clinic to seek medical care for HBV infection and thus did not include in-patients admitted at the medical emergency unit or on the medical wards for complications of hepatitis B infection. Neither did the study capture HBV patients who were not seeking hospital-based care at all. Thus, the results of this study may potentially underestimate the prevalence of advanced disease among HBsAg seropositive patients.

### 434 **Conclusions**

This study reports a high level of HBsAg positivity rate among close family members of HBV positive persons. Nonetheless, there is very low adherence to the requirement of screening of close family members of index cases. There is a very low treatment eligibility rate among patients seeking medical care for HBV infection. There was low prevalence of both HIV and HCV coinfections without any recorded cases of triple infections.

### 440 **References**

- 441 1. Razavi-Shearer, D., et al., *Global prevalence, cascade of care, and prophylaxis coverage*
- 442 *of hepatitis B in 2022: a modelling study.* The Lancet Gastroenterology & Hepatology,
- 443 2023. **8**(10): p. 879-907.
- 444 2. Schweitzer, A., et al., *Estimations of worldwide prevalence of chronic hepatitis B virus*
- 445 *infection: a systematic review of data published between 1965 and 2013.* The Lancet,
- 446 2015: p. 386(10003):1546-55.
- 447 3. Ott, J.J., et al., Global epidemiology of hepatitis B virus infection: new estimates of age-
- 448 *specific HBsAg seroprevalence and endemicity.* Vaccine, 2012. **30**(12): p. 2212-9.
- 449 4. WHO. *Hepatitis B, Key facts*. WHO 2019 July 18; Available from:
  450 https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
- 451 5. Venook, A.P., et al., *The incidence and epidemiology of hepatocellular carcinoma: a*452 *global and regional perspective.* Oncologist, 2010. **15 Suppl 4**(S4): p. 5-13.
- 453 6. Lavanchy, D., *Hepatitis B virus epidemiology, disease burden, treatment, and current and*454 *emerging prevention and control measures.* J Viral Hepat, 2004. 11(2): p. 97-107.
- 455 7. Sonderup, M.W. and C.W. Spearman, *Global Disparities in Hepatitis B Elimination-A*456 *Focus on Africa*. Viruses, 2022. 14(1).
- 457 8. Yang, W.T., et al., *Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma*458 *Development in Patients With Dual Hepatitis B and C Infection*. Medicine (Baltimore),
  459 2016. 95(10): p. e2995.
- Blankson, A., et al., *Sero-prevalence of Hepatitis B and C viruses in cirrhosis of the liver in Accra, Ghana.* Ghana medical journal., 2005: p. 39(4):132.
- 462 10. Nartey, Y.A., et al., *A nationwide cross-sectional review of in-hospital hepatitis B virus*463 *testing and disease burden estimation in Ghana, 2016-2021.* BMC Public Health, 2022.
- 464 **22**(1): p. 1-15.

- 465 11. Teye, J., *Ghana risks losing productive youth to Hepatitis*, in *Myjoyonline.com*. 2015.
- 466 12. Abesig, J., et al., Prevalence of viral hepatitis B in Ghana between 2015 and 2019: A
- 467 *systematic review and meta-analysis.* PloS one, 2020. **15**(6): p. e0234348.
- 468 13. Ofori-Asenso, R. and A.A. Agyeman, Hepatitis B in Ghana: a systematic review & meta-
- 469 *analysis of prevalence studies (1995-2015).* BMC Infect Dis, 2016. **16**: p. 130.
- 470 14. Organization, W.H. and *Global hepatitis report 2017*. 2017.
- 471 15. EASL, *Clinical Practice Guidelines on the management of hepatitis B virus infection.*472 Journal of hepatology, 2017: p. 67(2):370-98.
- 473 16. Terrault, N.A., et al., AASLD guidelines for treatment of chronic hepatitis B. Hepatology,
- 474 2016. **63**(1): p. 261-83.
- 475 17. Blumberg, B.S., *The discovery of Australia antigen and its relation to viral hepatitis*. 1971.
- 476 18. Saldanha, J., et al., An international collaborative study to establish a World Health
  477 Organization international standard for hepatitis B virus DNA nucleic acid amplification
- 478 *techniques.* Vox Sang, 2001. **80**(1): p. 63-71.
- 479 19. Wang, J., et al., Analytical comparison between two hematological analyzer systems:
  480 Mindray BC-5180 vs Sysmex XN-1000. J Clin Lab Anal, 2019. 33(8): p. e22955.
- 481 20. Branson, B.M., et al., *Revised recommendations for HIV testing of adults, adolescents,*
- 482 *and pregnant women in health-care settings*. MMWR Recomm Rep, 2006. 55(RR-14): p.
  483 1-17; quiz CE1-4.
- 484 21. Smith, B.D., et al., *Rapid diagnostic HCV antibody assays*. Antivir Ther, 2012. 17(7 Pt
  485 B): p. 1409-13.
- 486 22. Wai, C.T., et al., A simple noninvasive index can predict both significant fibrosis and
  487 *cirrhosis in patients with chronic hepatitis C.* Hepatology, 2003. 38(2): p. 518-26.
- 488 23. Organization, W.H., Guidelines for the prevention care and treatment of persons with
- 489 *chronic hepatitis B infection: Mar-15*. 2015: World Health Organization.

- 490 24. Howell, J., M. Lemoine, and M. Thursz, *Prevention of materno-foetal transmission of*
- 491 *hepatitis B in sub-Saharan Africa: the evidence, current practice and future challenges.* J

492 Viral Hepat, 2014. **21**(6): p. 381-96.

- 493 25. Antwi-Baffour, S.S., et al., Incidence of hepatitis B surface antigen among sickle cell
- 494 *disease patients receiving transfusion therapy*. Int J Biomed Sci Engineering, 2014. **2**(1):
- 495 p. 7-10.
- 496 26. Adjei, A.A., et al., *Correlates of HIV, HBV, HCV and syphilis infections among prison*497 *inmates and officers in Ghana: A national multicenter study.* BMC infectious diseases,
  498 2008. 8(1): p. 1-12.
- 499 27. Fenny, A.P., et al., *Who uses outpatient healthcare services under Ghana's health*500 *protection scheme and why?* BMC Health Serv Res, 2016. 16(1): p. 174.
- 501 28. Coombs, R.W., P.S. Reichelderfer, and A.L. Landay, *Recent observations on HIV type-1*502 *infection in the genital tract of men and women.* AIDS, 2003. 17(4): p. 455-80.
- 503 29. Baig, S., *Gender disparity in infections of Hepatitis B virus*. J Coll Physicians Surg Pak,
  504 2009. 19(9): p. 598-600.
- S05 30. Candotti, D. and J.P. Allain, *Transfusion-transmitted hepatitis B virus infection*. J Hepatol,
  2009. 51(4): p. 798-809.
- 507 31. Vittal, A. and M.G. Ghany, *WHO Guidelines for Prevention, Care and Treatment of*508 *Individuals Infected with HBV: A US Perspective.* Clin Liver Dis, 2019. 23(3): p. 417-432.
- 509 32. Kittner, J.M., et al., *Disclosure behaviour and experienced reactions in patients with HIV*
- 510 *versus chronic viral hepatitis or diabetes mellitus in Germany.* AIDS Care, 2013. 25(10):
  511 p. 1259-70.
- 512 33. Adjei, C.A., et al., "To die is better than to tell": reasons for and against disclosure of
- 513 *chronic hepatitis B status in Ghana*. BMC public health, 2020. **20**(1): p. 1-9.

- 514 34. Kafeero, H.M., et al., *Sero-prevalence of human immunodeficiency virus-hepatitis B virus*
- 515 (*HIV-HBV*) co-infection among pregnant women attending antenatal care (ANC) in sub-
- 516 Saharan Africa (SSA) and the associated risk factors: a systematic review and meta-
- 517 *analysis.* Virol J, 2020. **17**(1): p. 170.
- 518 35. Sofian, M., et al., Intra-familial Transmission of Hepatitis B Virus Infection in Arak,
- 519 *Central Iran*. Iran J Pathol, 2016. **11**(4): p. 328-333.
- 520 36. Mangowi, I., et al., *Hepatitis B virus infection, associated factors, knowledge and* 521 *vaccination status among household contacts of hepatitis B index cases in Mwanza,*
- 522 *Tanzania*. IJID Reg, 2024. **10**: p. 168-173.
- 523 37. Mahajan, A.P., et al., *Stigma in the HIV/AIDS epidemic: a review of the literature and* 524 *recommendations for the way forward.* AIDS, 2008. **22 Suppl 2**(Suppl 2): p. S67-79.
- 38. Adjei, C.A., et al., *Chronic Hepatitis B stigma in Ghana: a qualitative study with patients and providers*. BMJ Open, 2019. 9(6): p. e025503.
- 527 39. Lemoine, M., S. Eholie, and K. Lacombe, *Reducing the neglected burden of viral hepatitis*528 *in Africa: strategies for a global approach.* J Hepatol, 2015. 62(2): p. 469-76.
- 40. Kwasikumah, F., et al., Assessment of public opinion on the use of herbal medicine for the
- 530 treatment of sexually transmitted infections (STI) in accra. Traditional Medicine and
- 531 Modern Medicine, 2024. 7: p. 1-12.
- 41. Aziato, L. and H.O. Antwi, *Facilitators and barriers of herbal medicine use in Accra, Ghana: an inductive exploratory study.* BMC Complement Altern Med, 2016. 16: p. 142.
- 534 42. Amegbor, P.M., Understanding usage and preference for health care therapies in a
- 535 Ghanaian context: A pluralistic perspective. Norsk Geografisk Tidsskrift-Norwegian
- 536 Journal of Geography, 2017. **71**(5): p. 288-300.

- 43. Nartey, Y.A., et al., *A nationwide cross-sectional review of in-hospital hepatitis B virus*
- testing and disease burden estimation in Ghana, 2016 2021. BMC Public Health, 2022.

539 **22**(1): p. 2149.

- 540 44. Guirgis, M., et al., Barriers faced by migrants in accessing healthcare for viral hepatitis
- 541 *infection.* Intern Med J, 2012. **42**(5): p. 491-6.
- 542 45. Giles-Vernick, T., et al., Barriers to Linkage to Care for Hepatitis B Virus Infection: A
- 543 *Qualitative Analysis in Burkina Faso, West Africa.* Am J Trop Med Hyg, 2016. 95(6): p.
  544 1368-1375.
- 545 46. Wong, R.J., et al., Low rates of hepatitis B virus treatment among treatment-eligible
- 546 *patients in safety-net health systems.* Journal of Clinical Gastroenterology, 2022. **56**(4): p.
- 547 360-368.









